Capadenoson

Drug Profile

Capadenoson

Alternative Names: BAY 68-4986

Latest Information Update: 07 May 2013

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Class Ischaemic heart disorder therapies; Nitriles; Pyridines; Thiazoles
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Atrial fibrillation

Most Recent Events

  • 28 Mar 2011 No development reported - Phase-II for Atrial fibrillation in Germany (PO)
  • 13 Apr 2007 Data presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC-2007) added to the adverse events and Ischaemic Heart Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top